(Q77542483)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9812178%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9812178%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

1 reference

A Hsu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9812178%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

G R Granneman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9812178%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

R J Bertz

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9812178%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 October 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9812178%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9812178%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9812178%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

275-291

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9812178%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9812178%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003088-199835040-00002

6 December 2019

exact match

0 references

cites work

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

12 December 2020

Interaction of methadone with substrates of human hepatic cytochrome P450 3A4.

1 reference

12 December 2020

Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538).

1 reference

12 December 2020

Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.

1 reference

12 December 2020

HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes

1 reference

12 December 2020

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

12 December 2020

Clinical pharmacokinetics of nucleoside antiretroviral agents

1 reference

12 December 2020

Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans

1 reference

12 December 2020

Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay

1 reference

12 December 2020

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

1 reference

12 December 2020

Pharmacokinetic-interaction study of didanosine and ranitidine in patients seropositive for human immunodeficiency virus

1 reference

12 December 2020

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

1 reference

12 December 2020

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin

1 reference

12 December 2020

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

12 December 2020

Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients

1 reference

12 December 2020

Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy

1 reference

12 December 2020

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

1 reference

12 December 2020

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers

1 reference

12 December 2020

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial

1 reference

12 December 2020

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

12 December 2020

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

12 December 2020

Recent developments in HIV protease inhibitor therapy

1 reference

12 December 2020

In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates

1 reference

12 December 2020

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

1 reference

12 December 2020

HIV-1 protease inhibitors. A review for clinicians

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

1 reference

12 December 2020

1 reference

12 December 2020

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

1 reference

12 December 2020

Rifampin drug interactions

1 reference

12 December 2020

Cytochrome P450 isozymes and antiepileptic drug interactions

1 reference

12 December 2020

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

1 reference

12 December 2020

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

12 December 2020

Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

1 reference

12 December 2020

Pharmacokinetic interaction between ritonavir and clarithromycin

1 reference

12 December 2020

Single-dose pharmacokinetics of indinavir and the effect of food.

1 reference

12 December 2020

Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation

1 reference

12 December 2020

Time-course of interaction between carbamazepine and clonazepam in normal man

1 reference

12 December 2020

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

1 reference

12 December 2020

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

12 December 2020

Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir.

1 reference

12 December 2020

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

1 reference

12 December 2020

Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes

1 reference

12 December 2020

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

1 reference

12 December 2020

A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection

1 reference

12 December 2020

Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.

1 reference

12 December 2020

Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam

1 reference

12 December 2020

Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee

1 reference

12 December 2020

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

12 December 2020

Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin

1 reference

12 December 2020

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

12 December 2020

In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors

1 reference

12 December 2020

Structure-based, C2 symmetric inhibitors of HIV protease

1 reference

12 December 2020

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

12 December 2020

Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects

1 reference

12 December 2020

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine

1 reference

12 December 2020

Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients

1 reference

12 December 2020